For example, mutations in NPM1, CEBPA, and RUNX1 can identify specific subclass of AML, and mutations in FLT3, IDH1, IDH2, and JAK2 can guide targeted therapies for AML [3]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.